No. The announcement had nothing to do with AT1's partial-product (i.e. FebriDX). However, it is good to see that company doing better (rising from 1c, after dropping from ~$1 something).
We will see a rise when LDX gets CLIA waiver for FebriDX and when they announce partnerships.
Separately, I suspect that AT1's next announcements should be the TGA decision on the pregnancy kit, as well as guidance on the US FDA application for the pregnancy kit. Better AUS HIV sales wouldn't hurt either, as well as lower priced international sales.
AT1 FY21 - General Discussion + FA, page-2422
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 497908 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 67200 | 3 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable